Código QR (código de barras bidimensional)

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials

Abstract Introduction The ongoing KEEPsAKE 1 and 2 (KS1; KS2) trials evaluate the efficacy and safety of risankizumab in patients with psoriatic arthritis (PsA) who had an inadequate response to ≥ 1 conventional synthetic disease-modifying antirheumatic drug(s) (csDMARD-IR, KS1&2) and/or 1–2 biologi...

Fuld beskrivelse

Na minha lista:
Principais autores: Andrew Östör, Filip Van den Bosch, Kim Papp, Mauro Keiserman, Ricardo Blanco, Angela Crowley, Douglas White, Ana Biljan, Tshepiso Madihlaba, Kyle Carter, Fang Liu, Ahmed M. Soliman, Doug Ashley, Michael Chen, Lila Glotfelty, Alan Kivitz
Format: Artigo
Sprog:Inglês
Udgivet: Adis, Springer Healthcare 2025-09-01
Serier:Rheumatology and Therapy
Fag:
bDMARD-IR
csDMARD-IR
IL-23
KEEPsAKE 1
KEEPsAKE 2
Long-term treatment
Online adgang:https://doi.org/10.1007/s40744-025-00793-3
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker